RxDoctor Payments Data

Daniel Debo, DO

Gastroenterology · Montgomery, OHNPI 1447254040

Payments from drug & device makers

$7,240in general payments, 2019–2025

Across 458 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$796
  • Johnson & Johnson$764
  • Regeneron Healthcare Solutions, Inc.$663
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$449
  • QOL Medical, LLC$386
  • plus $2K from 26 others

What the payments were for

  • Speaking & faculty fees$190%
  • Food & beverage$7,222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,240 in reported general payments places this provider in the 65th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$104,623
Medicare patients
287
Services billed
2,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide21$25,813
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates78$5,065
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,096
Pantoprazole Sodium100$1,266
Famotidine50$1,214
Omeprazole100$1,085
CholestyramineCholestyramine (With Sugar)19$969
Mesalamine DrMesalamine19$779
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl59$712
Dicyclomine Hcl20$586
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl26$346
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl17$303
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg12$235
Sucralfate11$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,364$25,81321 claims
Braintree Laboratories, Inc.Sutab$32$2,09613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Montgomery

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →